Premium
MELK serves as a potent independent biomarker to predict survival of diffuse large B‐cell lymphoma patients treated with rituximab‐CHOP regimen
Author(s) -
Zhang Y.,
Zhou X.,
Li Y.,
Xu Y.,
Wang X.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2439_22
Subject(s) - diffuse large b cell lymphoma , international prognostic index , cancer research , oncology , biology , lymphoma , bcl6 , vincristine , survival analysis , medicine , immunology , cyclophosphamide , chemotherapy , b cell , germinal center , antibody